Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.
Wenyu FuYujianan ChenKaidi WangAubryanna HettinghouseWenhuo HuJing-Quan WangZi-Ning LeiZhe-Sheng ChenKenneth A StaplefordChuan-Ju LiuPublished in: Protein & cell (2020)